argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis at ACR Convergence 2026
Start here
argenx will present results from its Phase 3 ALKIVIA study of efgartigimod in autoimmune myositis at ACR Convergence 2026, the rheumatology meeting where the data will be shared as a late-breaking oral presentation, numbered LB24. Autoimmune myositis is a group of rare muscle-inflammatory diseases, and efgartigimod is argenx's lead FcRn blocker. The presentation slot signals that the findings are considered timely enough for a late-breaking designation. The data themselves have not yet been made public, so the trial's efficacy and safety outcomes, and their implications for regulatory filing in this indication, remain open questions until the congress takes place.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- globenewswire.comargenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Latereaking Oral Presentation at ACR Convergence 2026
argenx announced that Phase 3 ALKIVIA data for efgartigimod in autoimmune myositis will be presented as a late-breaking oral presentation (#LB24) at ACR Convergence 2026.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 20 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.